A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males

PHASE2CompletedINTERVENTIONAL
Enrollment

169

Participants

Timeline

Start Date

July 14, 2016

Primary Completion Date

March 15, 2018

Study Completion Date

May 22, 2018

Conditions
Alopecia
Interventions
DRUG

Setipiprant

Setipiprant tablets, orally, BID for 24 weeks.

DRUG

Placebo

Placebo tablets, orally, BID for 24 weeks.

DRUG

Finasteride

Finasteride tablet, orally, once daily for 24 weeks.

Trial Locations (18)

17033

Penn State Hershey Medical Center Dermatology Research Office, Hershey

24501

The Education & Research Foundation, Inc, Lynchburg

27157

Wake Forest University Health Sciences Department of Dermatology Medical Center Boulevard, Winston-Salem

29650

Radiant Research, Inc., Greer

44195

Cleveland Clinic, Dept of Dermatology, Cleveland

48038

Michigan Center for Skin Care Research, Clinton Township

55432

Minnesota Clinical Study Center, Fridley

55455

University of Minnesota Department of Dermatology Division of Clinical research, Minneapolis

60611

DeNova Research, Chicago

67207

Heartland Research Associates, LLC, Wichita

71913

Burke Pharmaceutical Research, Hot Springs

72205

Petrus Center for Aesthetic Surgery & Hair Transplantation, Little Rock

77494

Suzzane Bruce and Associates P.A., The Center for Skin Research, Katy

78759

DermResearch, Inc, Austin

92123

Therapeutics Clinical Research, San Diego

95405

Radiant Research, Inc., Santa Rosa

97210

NW Dermatology and Research Center, Portland

97223

Oregon Medical Research Center, Portland

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY